Daniel Hermanson

2.5k total citations
15 papers, 1.3k citations indexed

About

Daniel Hermanson is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Daniel Hermanson has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Molecular Biology. Recurrent topics in Daniel Hermanson's work include Cannabis and Cannabinoid Research (8 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Daniel Hermanson is often cited by papers focused on Cannabis and Cannabinoid Research (8 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Daniel Hermanson collaborates with scholars based in United States, Canada and Germany. Daniel Hermanson's co-authors include Lawrence J. Marnett, Sachin Patel, Joyonna Gamble‐George, Surajit Banerjee, Rebecca J. Bluett, Nolan D. Hartley, Roger Colbran, Brian C. Shonesy, Shu Xu and Jeffery J. Prusakiewicz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Daniel Hermanson

14 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Hermanson United States 14 821 353 295 147 145 15 1.3k
Spyros P. Nikas United States 24 1.2k 1.5× 767 2.2× 595 2.0× 199 1.4× 193 1.3× 82 1.9k
Oscar Sasso Italy 22 943 1.1× 382 1.1× 492 1.7× 81 0.6× 94 0.6× 27 1.7k
Hamed Shafaroodi Iran 22 343 0.4× 492 1.4× 345 1.2× 64 0.4× 113 0.8× 94 1.5k
Stefania Ruiu Italy 21 432 0.5× 551 1.6× 337 1.1× 106 0.7× 118 0.8× 61 1.2k
Eric L. Barker United States 20 443 0.5× 813 2.3× 637 2.2× 77 0.5× 67 0.5× 42 1.6k
Guillermo Moreno‐Sanz United States 17 822 1.0× 280 0.8× 219 0.7× 134 0.9× 107 0.7× 26 1.0k
Erika Gyengési Australia 27 324 0.4× 311 0.9× 651 2.2× 144 1.0× 136 0.9× 51 2.2k
Séverine Vandevoorde Belgium 18 1.1k 1.3× 341 1.0× 244 0.8× 112 0.8× 178 1.2× 21 1.3k
A. Milone Italy 15 699 0.9× 392 1.1× 208 0.7× 110 0.7× 97 0.7× 27 1.2k
Marta Kruk-Słomka Poland 20 386 0.5× 340 1.0× 315 1.1× 90 0.6× 120 0.8× 43 972

Countries citing papers authored by Daniel Hermanson

Since Specialization
Citations

This map shows the geographic impact of Daniel Hermanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Hermanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Hermanson more than expected).

Fields of papers citing papers by Daniel Hermanson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Hermanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Hermanson. The network helps show where Daniel Hermanson may publish in the future.

Co-authorship network of co-authors of Daniel Hermanson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Hermanson. A scholar is included among the top collaborators of Daniel Hermanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Hermanson. Daniel Hermanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hakimi, Amirmansoor, et al.. (2025). Whole Blood Proteome Dynamics Defines Predictive Diagnostic and Prognostic Signatures of Cryptococcal Infection. Molecular & Cellular Proteomics. 24(11). 101083–101083.
2.
Serrano, Lia R., Trenton M. Peters-Clarke, Tabiwang N. Arrey, et al.. (2024). The One Hour Human Proteome. Molecular & Cellular Proteomics. 23(5). 100760–100760. 23 indexed citations
3.
Parker, Christopher G., Christian A. Kuttruff, Andrea Galmozzi, et al.. (2017). Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs. ACS Central Science. 3(12). 1276–1285. 53 indexed citations
4.
Wang, Bo, Xin Rong, Mark A. Duerr, et al.. (2016). Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet. Cell Metabolism. 23(3). 492–504. 94 indexed citations
5.
Gray, Jennifer M., Haley A. Vecchiarelli, Maria Morena, et al.. (2015). Corticotropin-Releasing Hormone Drives Anandamide Hydrolysis in the Amygdala to Promote Anxiety. Journal of Neuroscience. 35(9). 3879–3892. 195 indexed citations
6.
Mitchener, Michelle M., Daniel Hermanson, H. Alex Brown, et al.. (2015). Competition and allostery govern substrate selectivity of cyclooxygenase-2. Proceedings of the National Academy of Sciences. 112(40). 12366–12371. 24 indexed citations
7.
Xu, Shu, Daniel Hermanson, Surajit Banerjee, et al.. (2014). Oxicams Bind in a Novel Mode to the Cyclooxygenase Active Site via a Two-water-mediated H-bonding Network. Journal of Biological Chemistry. 289(10). 6799–6808. 101 indexed citations
8.
Hermanson, Daniel, Joyonna Gamble‐George, Lawrence J. Marnett, & Sachin Patel. (2014). Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends in Pharmacological Sciences. 35(7). 358–367. 93 indexed citations
9.
Shonesy, Brian C., Rebecca J. Bluett, Teniel S Ramikie, et al.. (2014). Genetic Disruption of 2-Arachidonoylglycerol Synthesis Reveals a Key Role for Endocannabinoid Signaling in Anxiety Modulation. Cell Reports. 9(5). 1644–1653. 123 indexed citations
10.
Bluett, Rebecca J., Joyonna Gamble‐George, Daniel Hermanson, et al.. (2014). Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Translational Psychiatry. 4(7). e408–e408. 114 indexed citations
11.
Hermanson, Daniel, Nolan D. Hartley, Joyonna Gamble‐George, et al.. (2013). Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nature Neuroscience. 16(9). 1291–1298. 102 indexed citations
12.
Windsor, Matthew A., Daniel Hermanson, Philip J. Kingsley, et al.. (2012). Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. ACS Medicinal Chemistry Letters. 3(9). 759–763. 33 indexed citations
13.
Hermanson, Daniel & Lawrence J. Marnett. (2011). Cannabinoids, endocannabinoids, and cancer. Cancer and Metastasis Reviews. 30(3-4). 599–612. 126 indexed citations
14.
Duggan, Kelsey C., Daniel Hermanson, Joel Musee, et al.. (2011). (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nature Chemical Biology. 7(11). 803–809. 151 indexed citations
15.
Тимофеева, О. А., David Sanders, Daniel Hermanson, et al.. (2008). Persistent behavioral alterations in rats neonatally exposed to low doses of the organophosphate pesticide, parathion. Brain Research Bulletin. 77(6). 404–411. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026